Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University of New Mexico |
---|---|
Information provided by: | University of New Mexico |
ClinicalTrials.gov Identifier: | NCT00250042 |
1.0 OBJECTIVES 1.1 To test the activity of arsenic trioxide in combination with imatinib in patients with CML with cytogenetic evidence of residual disease. 1.2 To determine the toxicity associated with this therapy.
Condition | Intervention | Phase |
---|---|---|
Leukemia, Other Cancer |
Drug: Gleevec and Arsenic Trioxide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail to Achieve a Complete Response to Initial Gleevec Treatment |
Enrollment: | 6 |
Study Start Date: | April 2004 |
Study Completion Date: | March 2006 |
Primary Completion Date: | April 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
Hematologic relapse defined as the appearance of any of the following, confirmed by a second determination > 1 month later:
Exclusion Criteria:
United States, New Mexico | |
University of New Mexico | |
Albuquerque, New Mexico, United States, 87131 | |
New Mexico Cancer Care Associates | |
Santa Fe, New Mexico, United States, 87505 |
Principal Investigator: | Ian Rabinowitz, MD | University of New Mexico |
Responsible Party: | University of New Mexico - CRTC ( Ian Rabinowitz, M.D. ) |
Study ID Numbers: | 0604C |
Study First Received: | November 3, 2005 |
Last Updated: | October 1, 2008 |
ClinicalTrials.gov Identifier: | NCT00250042 History of Changes |
Health Authority: | United States: Institutional Review Board |
Imatinib Leukemia Arsenic trioxide Protein Kinase Inhibitors |
Imatinib Leukemia Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Therapeutic Uses Arsenic trioxide Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |